Health News
FDA Grants Janssen Research & Development Breakthrough Therapy Designation for Daratumumab
Janssen Research & Development, LLC (Janssen) announced the US Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for daratumumab for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), or who are double refractory to a PI and IMiD.
FDA Limits Duration and Usage of Samsca
The US Food and Drug Administration (FDA) has determined that the drug Samsca (tolvaptan) should not be used for longer than 30 days and should not be used in patients with underlying liver disease because it can cause liver injury, potentially requiring liver transplant or death.
FDA Approves Kcentra
The US Food and Drug Administration today approved Kcentra (Prothrombin Complex Concentrate, Human) for the urgent reversal of vitamin K antagonist (VKA) anticoagulation in adults with acute major bleeding.
Cancer Rx Prices Too High!
Today, people with chronic myeloid leukemia (CML) are leading pretty much normal lives. They can thank a variety of medications for being alive.
Winning the War against Childhood Cancer
Children shouldn’t experience cancer. The disease should be left to those who’ve spent a few more years on this earth.
Back to Hospital after Stem Cell Transplant
Stem cell transplants can – and do – save the lives of very sick kids. New research has discovered that the transplant is often just the start of hospital stays for these young patients.
Spreading Sarcoidosis Awareness
When you think of the most-well known medical conditions in the world, a disorder called sarcoidosis probably does not come to mind. That fact is one reason why the month of April is recognized as National Sarcoidosis Awareness month.
Completely New Way to Treat Childhood Cancer
Scientists have entered a brave new world when it comes to treating childhood leukemia. New therapies now being tested may completely change the way one type of blood cancer is treated in children.
Pfizer’s BOSULIF Receives Conditional Marketing Authorization From The European Commission
Pfizer Inc. announced today that the European Commission (EC) has granted conditional marketing authorization for BOSULIF ® (bosutinib) in the European Union (EU) for the treatment of adult patients with chronic phase (CP), accelerated phase (AP) and blast phase (BP) Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML) previously treated with one or more tyrosine kinase inhibitor(s) (TKIs) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.
Personalizing Blood Cancer Treatment
Huge advances have been made in the understanding of multiple myeloma. There are a variety of approaches for treating this blood cancer. The trick is to provide what’s best for the individual patient.